APG 1387

Drug Profile

APG 1387

Alternative Names: APG-1387; SM-1387

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jiangsu Ascentage Pharma
  • Class Antineoplastics
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 15 Nov 2017 US FDA accepts IND for APG 1387 for Solid tumours (Late-stage) and Haematological malignancies for review
  • 29 Sep 2016 Phase-I clinical trials in Solid tumours in China (IV) before September 2016
  • 29 Sep 2016 Ascentage Pharma plans clinical trial (In combination) for Breast cancer and Ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top